JPWO2020031936A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020031936A5 JPWO2020031936A5 JP2020535747A JP2020535747A JPWO2020031936A5 JP WO2020031936 A5 JPWO2020031936 A5 JP WO2020031936A5 JP 2020535747 A JP2020535747 A JP 2020535747A JP 2020535747 A JP2020535747 A JP 2020535747A JP WO2020031936 A5 JPWO2020031936 A5 JP WO2020031936A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- amino acid
- drug conjugate
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024043043A JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A JP2024178243A (ja) | 2018-08-06 | 2024-09-13 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018147582 | 2018-08-06 | ||
| JP2018147582 | 2018-08-06 | ||
| PCT/JP2019/030635 WO2020031936A1 (ja) | 2018-08-06 | 2019-08-05 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043043A Division JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2020031936A1 JPWO2020031936A1 (ja) | 2021-08-10 |
| JPWO2020031936A5 true JPWO2020031936A5 (https=) | 2022-08-15 |
| JP7458981B2 JP7458981B2 (ja) | 2024-04-01 |
Family
ID=69414755
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535747A Active JP7458981B2 (ja) | 2018-08-06 | 2019-08-05 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024043043A Pending JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A Pending JP2024178243A (ja) | 2018-08-06 | 2024-09-13 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024043043A Pending JP2024075668A (ja) | 2018-08-06 | 2024-03-19 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
| JP2024158824A Pending JP2024178243A (ja) | 2018-08-06 | 2024-09-13 | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12497465B2 (https=) |
| EP (1) | EP3834843A4 (https=) |
| JP (3) | JP7458981B2 (https=) |
| KR (1) | KR20210042120A (https=) |
| CN (1) | CN112512587A (https=) |
| AU (2) | AU2019320336B2 (https=) |
| BR (1) | BR112021001750A2 (https=) |
| CA (1) | CA3108754A1 (https=) |
| EA (1) | EA202190471A1 (https=) |
| TW (1) | TW202019487A (https=) |
| WO (1) | WO2020031936A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018320470B2 (en) * | 2017-08-23 | 2025-04-24 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate preparation and lyophilization for same |
| EA202190471A1 (ru) * | 2018-08-06 | 2021-05-24 | Дайити Санкио Компани, Лимитед | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина |
| IL288485B2 (en) * | 2019-05-29 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-TROP2 antibody conjugates - a drug for use in cancer treatment |
| CN115348971A (zh) * | 2020-03-30 | 2022-11-15 | 国立研究开发法人国立癌症研究中心 | 抗体-药物缀合物 |
| CN116390771A (zh) | 2020-07-13 | 2023-07-04 | 瑞泽恩制药公司 | 与蛋白中的谷氨酰胺残基缀合的喜树碱类似物及其用途 |
| JP2023545096A (ja) * | 2020-10-09 | 2023-10-26 | アストラゼネカ ユーケー リミテッド | 抗体－薬物コンジュゲート及びｐａｒｐ１選択的阻害薬の組み合わせ |
| WO2022099762A1 (zh) * | 2020-11-12 | 2022-05-19 | 博瑞生物医药（苏州）股份有限公司 | 一种抗体偶联物中间体及其制备方法 |
| JP7564958B2 (ja) * | 2020-12-18 | 2024-10-09 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | Ｂ７－ｈ３を標的とする抗体薬物複合体、その製造方法と使用 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| CN117881431A (zh) * | 2021-08-24 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
| MX2024003277A (es) * | 2021-09-15 | 2024-04-04 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo-farmaco para usarse en metodos de tratamiento del cancer resistente a la quimioterapia. |
| CN119255825A (zh) * | 2022-05-24 | 2025-01-03 | 第一三共株式会社 | 抗-cdh6抗体-药物缀合物的剂量方案 |
| WO2024008102A1 (en) * | 2022-07-05 | 2024-01-11 | Wuxi Xdc (Shanghai) Co., Ltd. | Linker for conjugation |
| WO2024190815A1 (ja) * | 2023-03-14 | 2024-09-19 | 第一三共株式会社 | 抗ｃｄｈ６抗体－薬物コンジュゲートとｖｅｇｆ阻害剤の組み合わせ |
| AU2024248799A1 (en) * | 2023-03-31 | 2025-10-23 | Daiichi Sankyo Company, Limited | Combination of anti-CDH6 antibody-drug conjugate and HIF-2alpha inhibitor |
| WO2025002310A1 (zh) * | 2023-06-29 | 2025-01-02 | 石药集团巨石生物制药有限公司 | 抗体-药物偶联物及其用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| CN100340575C (zh) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | 人源化抗ErbB2抗体及其在制备药物中的应用 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| CA2486285C (en) | 2004-08-30 | 2017-03-07 | Viktor S. Goldmakher | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| DE602005022928D1 (de) | 2004-11-30 | 2010-09-23 | Abgenix Inc | Antikörper gegen gpnmb und ihre verwendungen |
| DK1912677T3 (da) | 2005-06-20 | 2014-01-13 | Psma Dev Company L L C | PSMA-antistof-lægemiddel-konjugater |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| IN2014DN06806A (https=) | 2012-02-10 | 2015-05-22 | Univ Maryland | |
| ES2773710T3 (es) | 2012-10-11 | 2020-07-14 | Daiichi Sankyo Co Ltd | Enlazadores para conjugados de anticuerpo - fármaco |
| WO2014061277A1 (ja) | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート |
| CN103239455A (zh) * | 2012-12-24 | 2013-08-14 | 苏州大学 | 有协同治疗效果和高载药量的多组分纳米药物的制备方法 |
| AU2014371934B2 (en) | 2013-12-25 | 2020-01-23 | Daiichi Sankyo Company, Limited | Anti-TROP2 antibody-drug conjugate |
| IL310627B2 (en) * | 2014-01-31 | 2026-04-01 | Daiichi Sankyo Co Ltd | Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof |
| JP2017114763A (ja) | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| EP3130608B1 (en) | 2014-04-10 | 2019-09-04 | Daiichi Sankyo Co., Ltd. | (anti-her2 antibody)-drug conjugate |
| KR102445502B1 (ko) | 2014-04-10 | 2022-09-21 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| MA40513A (fr) | 2014-08-12 | 2017-06-21 | Novartis Ag | Conjugués médicament-anticorps anti-cdh6 |
| HUE049175T2 (hu) | 2014-09-23 | 2020-09-28 | Hoffmann La Roche | Eljárás anti-CD79b immunkonjugátumok alkalmazására |
| JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| CN116440279B (zh) | 2015-09-17 | 2026-02-24 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| KR20180123214A (ko) | 2015-12-09 | 2018-11-15 | 난트 홀딩스 아이피, 엘엘씨 | Her2 양성 전이성 유방암의 치료를 위한 조성물 및 방법 |
| PE20231050A1 (es) * | 2016-03-02 | 2023-07-11 | Eisai Randd Man Co Ltd | Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso |
| US11273155B2 (en) * | 2016-12-12 | 2022-03-15 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and immune checkpoint inhibitor |
| JP6679762B2 (ja) * | 2017-01-17 | 2020-04-15 | 第一三共株式会社 | 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート |
| TW202532104A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| IL324591A (en) | 2017-08-31 | 2026-01-01 | Daiichi Sankyo Co Ltd | Improved antibody-drug conjugate production methods |
| EA202190471A1 (ru) * | 2018-08-06 | 2021-05-24 | Дайити Санкио Компани, Лимитед | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина |
-
2019
- 2019-08-05 EA EA202190471A patent/EA202190471A1/ru unknown
- 2019-08-05 TW TW108127750A patent/TW202019487A/zh unknown
- 2019-08-05 CA CA3108754A patent/CA3108754A1/en active Pending
- 2019-08-05 BR BR112021001750-0A patent/BR112021001750A2/pt unknown
- 2019-08-05 CN CN201980052170.5A patent/CN112512587A/zh active Pending
- 2019-08-05 WO PCT/JP2019/030635 patent/WO2020031936A1/ja not_active Ceased
- 2019-08-05 KR KR1020217006189A patent/KR20210042120A/ko not_active Ceased
- 2019-08-05 US US17/266,465 patent/US12497465B2/en active Active
- 2019-08-05 JP JP2020535747A patent/JP7458981B2/ja active Active
- 2019-08-05 EP EP19847036.1A patent/EP3834843A4/en active Pending
- 2019-08-05 AU AU2019320336A patent/AU2019320336B2/en active Active
-
2024
- 2024-03-19 JP JP2024043043A patent/JP2024075668A/ja active Pending
- 2024-09-13 JP JP2024158824A patent/JP2024178243A/ja active Pending
-
2025
- 2025-09-04 AU AU2025226765A patent/AU2025226765A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020031936A5 (https=) | ||
| JPWO2020122034A5 (https=) | ||
| JP2025041725A5 (https=) | ||
| AU2019411289B2 (en) | Improved cell-targeting binding molecule | |
| JP7458981B2 (ja) | 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ | |
| JP6328649B2 (ja) | 薬物−タンパク質コンジュゲート | |
| HRP20231609T1 (hr) | Konjugati lijeka koji sadrže antitijela protiv klaudina 18.2 | |
| JP6473138B2 (ja) | 癌、特に前立腺癌を標的とする合成抗体模倣化合物（ＳｙＡＭ） | |
| JP2008546792A5 (https=) | ||
| JP2020515578A5 (https=) | ||
| JP2013100314A5 (https=) | ||
| JP2017528418A5 (https=) | ||
| JP2020524675A5 (https=) | ||
| CA2967077A1 (en) | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin | |
| TWI838358B (zh) | 疏水性奧瑞他汀(auristatin)f化合物及其結合物 | |
| JP2018537975A5 (https=) | ||
| JP2015500287A (ja) | 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法 | |
| RU2016150377A (ru) | Сайт-специфичная конъюгация линкерных лекарственных препаратов с антителами и получаемые в результате adc | |
| JP2018509394A5 (https=) | ||
| JP2016511637A5 (https=) | ||
| JP2012522512A5 (https=) | ||
| US20170281787A1 (en) | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin | |
| JP2014508767A (ja) | 改善されたリンケージを有するアマトキシン複合体 | |
| JPWO2020027100A5 (https=) | ||
| JPWO2022102634A5 (https=) |